| 2012 | | Leukemia and Lymphoma Society
Tawanda Bryant |

[Leukemia and Lymphoma Society] | The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improves the quality of life of patients and their families. Providing free information and support services, Leukemia and Lymphoma funds lifesaving blood cancer research around the world. |

LEUKEMIA & LYMPHOMA SOCIETY
TAWANDA BRYANT
11410 COUNTY ROAD 20
BOLIGEE, AL 35443
(205) 336-9851 tbryant3030@yahoo.com LEADERSHIP and ORGANIZATIONAL MAR12 SEC AA
March 9, 2012
INSTRUCTOR: SHAROLYN HERGOTT

LEUKEMIA & LYMPHOMA SOCIETY
I have picked this organization because my best friend passed away last year with leukemia and I wanted to find out more on this disease and what I can do to help. Been passionate and concern about not only her health but the health of her kids, my research will show why it is important to me as well as others.
Having a passion for helping other in any way I can is what I am going for. I also like the face that I can somewhat relate to their illness and pain they endure within their life. I would love to find a quicker cure for these diseases, but I know others are working on something better. Having someone close to you with any type of disease, not just leukemia or lymphoma is hard to take in and understand.
Having the ability to communicate, have critical thinking, collaboration, and the ability to problem solve is what I aim for. What I do will reflect on others within the society as well as patients and families. Raising money to help families who can’t get the medication needed, rides to and from their doctor appointments and everything they have to do is my goal at “Leukemia & Lymphoma Society”.
If you care and can share the value and thrive to make a real impact, this is the time to make a difference in your life, in your career. When someone asks me, “What do you do for a living”? I want to say, “I find a cure for cancer”.
Working for LLS will give me the opportunity to understand why this society can and accept as many employees as possible. I understand they encourage ever individual to apply for open positions regardless of their race, sexual orientation, national origin, gender, color, disability, age, and veteran status.
There are some good benefits when working for LLS. The benefits have a comprehensive benefit that touches all areas of their lives. The benefits include: * Health plan * Dental plan * Liberal vacation * Holiday, sick and personal time * Life insurance * Short term disability * Long term disability * Annuity plan * Pension plan * Flexible spending accounts * Employee assistance program * Business casual dress * LEUKEMIA & LYMPHOMA SOCIETY
Mission and Goals
The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.
LLS are the world's largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Our Key Priorities will ensure that: The Leukemia & Lymphoma Society helps blood cancer patients live better, longer lives.

* Advance the diagnosis and treatment of blood cancers through continued funding of academic research, the therapy acceleration program and other special initiatives * Proactively establish a research agenda and direct a portion of research spending to specific areas of unmet medical need for leukemia, lymphoma & myeloma * Participate directly in blood cancer therapy development by expanding research beyond academic collaborations and biotech partnerships to include pharmaceutical companies and/or venture capitalists
Patient Services * Develop a services agenda for patients and their families to address their information and support needs * Inform blood cancer patients and improve access to the latest individual therapy options and blood cancer clinical trials * LLS is the key source of information and services for patients throughout their cancer journey
Public Policy * Increase funding for blood cancer research from non-LLS sources and accelerate the development of blood cancer therapies * Encourage an effective and science-driven regulatory system for efficient review of new blood cancer therapies * Ensure patients have insurance coverage for their treatments and well-coordinated and high quality cancer care
Revenue, Marketing and Field Management * Develop models for revenue growth and allocation among sources to guide future plans * Increase public awareness of LLS as the leading non-profit funding impactful research that is accelerating the development of new therapies and treatments for blood cancer patients * Increase public awareness of the impact blood cancer research is having on patients beyond those for whom they were first developed
Information Technology * Deliver superior services to LLS through its solutions and platforms * Continue to execute plans in place and find new opportunities to partner with the business units
Human Resources * Top-grade all talent in LLS; hire, inspire and retain "A" talent for all positions * Transform the Human Resources department into a proactive service organization * Strengthen a performance-driven culture * Achieve "best in class" level HR processes from on-boarding to out-placement * Expand diversity from top to bottom
Finance
* Minimize labor-intensive transactions and transaction processing * Greatly reduce staff time spent gathering, consolidating, forecasting and budgeting, actual and operational data * Provide analyses and predictive models that will help LLS solve problems, gain marketplace advantage, and support new initiatives.

LEUKEMIA & LYMPHOMA SOCIETY
Research Successes Programs and Highlights
At The Leukemia & Lymphoma Society (LLS) we're committed to funding research to help cure leukemia, lymphoma and myeloma and related malignancies and improve quality of life for patients diagnosed with these cancers.
When LLS was founded in 1949, a blood cancer diagnosis was almost always fatal. Thanks in part to innovative research funded by LLS, survival rates have doubled, tripled and even quadrupled for blood cancer patients.
Our Investment
In fiscal year 2011, LLS invested more than $76 million in blood cancer research. * Acute myeloid leukemia (AML), $18.2 million * Non-Hodgkin lymphoma (NHL), $15.7 million * Myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD), $10.5 million * Acute lymphoblastic leukemia (ALL), $9.8 million * Myeloma, $8.4 million * Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), $6.4 million * Chronic myeloid leukemia (CML), $4.3 million * Hodgkin lymphoma (HL), $3.2 million
Milestones
LLS are a driving force behind breakthroughs in treating blood cancer patients. Below are just a few highlights that showcase the progress that's been made during LLS's six decades of relentlessly focused research support.
-------------------------------------------------
The 1950s
The first chemotherapy drugs were developed for lymphoma and leukemia patients, including children. William Dameshek, M.D., Joseph Burchenal, M.D., George Hitchings, Ph.D. and Gertrude Elion, D.Sc. were leaders in this new field. Drs. Hitchings and Elion received Nobel prizes for their work, and helped guide LLS research funding in the early years.
-------------------------------------------------
The 1960s
The first combination chemotherapy was developed for childhood leukemia patients. Emil Frei, M.D., James Holland, M.D. and Emil Freireich, M.D. led the effort and Dr. Freireich advised LLS research programs from our inception.
-------------------------------------------------
The 1970s
The first successful bone marrow transplants were performed. E. Donnall Thomas, M.D. served as long-time advisor to LLS and received the 1990 Nobel Prize for his breakthrough work.
-------------------------------------------------
The 1980s
Cancer-causing "ontogenesis" was discovered. Geoffrey Cooper, Ph.D. and J. Michael Bishop, M.D. were among the leaders of this new field; both served as LLS advisors.
-------------------------------------------------
The 1990s to present
Molecular understandings of normal and malignant blood cells make new "targeted" anti-cancer drug therapies and immune-stimulating therapies possible, as well as supportive-care "growth factors" that can revitalize patients' blood systems after chemo- and radiation therapies.
Understanding which genetic and molecular abnormalities cause particular blood cancers has more recently led to new targeted drugs that selectively kill cancer cells, generally sparing normal cells and causing fewer side-effects than previous standard therapies. LLS funded these advances at critical points. What's more, many of the blood cancer treatments we've funded have gone on to benefit patients who have other types of cancer.
Below are highlights of several recent successes and new directions.
Gleevec®: A Revolutionary Drug for CML Patients
Since its approval by the Food and Drug Administration (FDA) in 2001, Gleevec® has become the standard first-line therapy for newly diagnosed chronic myeloid leukemia (CML) patients. LLS helped advance this groundbreaking targeted therapy and supported the researchers who helped develop the more recently approved drugs, Sprycel® and Tasigna®. These drugs make it possible for patients to survive many years with good quality of life. The 10-year survival rate has been remarkably improved, from approximately one in ten to nearly nine in ten for chronic phase CMLpatients (including children). Gleevec® is also approved for patients with rare skin and stomach tumors, and showing promise in many other cancers.
Velcade®: Improved Outcomes for Myeloma Patients
Before Velcade® was approved in 2008 as a first-line therapy for myeloma; patients' median survival rate was less than three years. Today, thanks to Velcade® and other new targeted drugs, people with myeloma have a median survival rate that's three times longer, and they are living with better quality of life since the drugs are less toxic than previous treatments. Velcade® is also approved for people with mantle cell lymphoma, and is being tested as a treatment for other cancers including other lymphomas and leukemia’s.
Rituxan®: A Targeted Therapy for Lymphoma Patients
Rituxan®, a monoclonal antibody drug, was FDA approved for follicular non-Hodgkin lymphoma (NHL) patients in 1997. In fact, it was the very first targeted drug approved in the U.S. LLS-funded researchers found that Rituxan® can dramatically improve chemotherapy effectiveness, and the FDA approved Rituxan® to be used in combination with other chemotherapy drugs for people with follicular lymphoma and other non-Hodgkin lymphoma types. It's contributed to a doubling of the survival rate for NHL patients, and is now also FDA approved as a treatment for patients with chronic or Hodgkin lymphoma.
Immunotherapy’s: Building a Stronger Immune System
Many people with blood cancers suffer from weakened immune systems caused by immune (white blood) cells becoming cancerous and overwhelming normal immune cells, and/or by the powerful treatments that cancer patients receive. Our researchers are working to (1) target the malignant immune cells while leaving healthy cells untouched and (2) strengthen patients' healthy immune cells through the use of vaccines, antibodies or growth factors. Immunotherapy’s can reduce patients' risks for life-threatening infections and effectively fight the cancers too.
Making Today's Therapies Safer
Beyond debilitating a patient's immune system, standard cancer treatments can cause other serious long. While supporting the development of entirely new targeted therapies and immunotherapy’s, LLS is also funding researchers who are working to learn how to predict, manage and even prevent these effects that reduce a patient's quality of life or even threaten their life.
For example, aggressive therapies for acute lymphoblastic leukemia (ALL) save many children with this cancer, but can cause significant medical complications. While some LLS-funded experts are developing new, less toxic treatments for pediatric ALL, other LLS investigators are discovering genetic risk factors that can help predict problems before they happen and treatments that reduce the severity of late treatment effects when they occur.
The Therapy Acceleration Program: Speeding Up Progress
Despite so many advances, blood cancer research can be a slow-moving process. Relentless in our determination to get better treatments to the patients who need them, we launched the Therapy Acceleration Program in 2007. Its goal is to bring more promising new treatments to more patients faster, by: * providing the funding and support needed to help researchers bring their projects closer to the product stage, * partnering with biotechnology companies to develop cutting-edge therapies that might not otherwise reach blood cancer patients, * Overcoming obstacles that may prevent patients from participating in clinical trials that can provide the best possible treatment for many patients.
LEUKEMIA and LYMPHOMA SOCIETY
History of Leukemia and Lymphoma Society
The Leukemia and Lymphoma Society was born out of a family’s grief following the death of their teenage son.
Robert Roesler de Villiers son of a well-to-do New York family was only 16 when he quickly succumbed to leukemia in 1944. Five years later, frustrated by the lack of effective treatments for what was then considered a hopeless disease, parents Rudolph and Antoinette de Villiers started a fundraising and education organization in their son's name.
Headquartered in a small Wall Street office, the Robert Roesler de Villiers Foundation had only a few volunteers and a tiny budget. The task was daunting. Most leukemia patients, especially children, died within three months. Even by the mid-1950s, when the first-generation chemotherapy drugs began appearing, the disease remained a stubborn challenge. The Foundation reported in its 1955 annual report: "As of this date, Leukemia is 100% fatal. This is almost a unique situation among the many diseases to which man is susceptible."
Driven by the de Villiers' nearly boundless belief that leukemia and other blood cancers were indeed curable, the Foundation grew steadily, opening its first chapters in the New York City area. The organization, after changing its name to The Leukemia Society, was renamed The Leukemia Society of America in the 1960s to communicate a broad, national reach.

What is Leukemia?
Leukemia is the most common blood cancer. According to the National Cancer Institute, 29,000 adults and 2,000 children are diagnosed with the disease each year. If you or someone love is affected by leukemia, you’ll want answers.
Leukemia & Lymphoma Society covers and explains four different types of leukemia: Acute Myelogenous Leukemia (AML), Acute Lymphocytic (ALL), Chronic Myelogenous Leukemia (CML) and Chronic Lymphocytic Leukemia (CLL).
Other societies that offer the help needed to understand and get the help needed are as followed: * National Cancer Institute * Mayo Clinic * Medline Plus

Leukemia Symptoms and Diagnosis
Leukemia symptoms can vary based on the patient, but frequent infections, weakness, bone and joint pain, and swollen lymph nodes are commonly experienced effects. Use the sites below to learn the common signs and symptoms of leukemia, and get accounts of how it's diagnosed.
Insights for Leukemia Symptoms and Diagnosis * Leukemia generally requires multiple tests to diagnose. These Web sites include information about the various tests your doctor may perform. Due to the fact that different physicians and different types of leukemia require different tests, patients may find they have to undergo a variety of tests before receiving a final diagnosis.

CureResearch.com breaks down the symptoms of leukemia by system and body part. The symptoms include links to more detailed information about the condition. The margins are littered with Google ads at the top, but keep scrolling down and you'll find a comprehensive list of symptoms.

MedicineNet.com gives an overview of the different types of tests your physician might use to diagnose leukemia. The Web site includes links to more information about the tests, such as how they're performed and how samples are obtained.

Oncology Channel includes scientific information about leukemia diagnostic tests, such as specific measures of red blood cells. The definitions of the tests are fairly detailed and may include terms that require a layman to use a medical dictionary.

Leukemia Treatment

Leukemia treatment varies depending on the type of leukemia, the stage of the disease and the patient's individual factors. Nonetheless, there are some common treatments, such as chemotherapy, biological therapy and radiation therapy that are used for leukemia. Use the sites below to learn more about leukemia treatment.
Insights for Leukemia Treatment * The sites in this section provide an overview of the variety of leukemia treatment options available. Researching individual leukemia treatments will yield deeper information about the preparation and procedure specific to that treatment.

MD Anderson Cancer Center at The University of Texas provides a simple overview of leukemia treatment, written for the layman. The Web site lists various treatments, and explains how these procedures are performed in easy-to-understand terms.

The Leukemia & Lymphoma Society covers various types of leukemia treatment, as well as detailed information about the procedures. Use the links to learn how each procedure is performed, how to prepare for it and how it treats the disease.

National Cancer Institute provides treatment facts for both the patient and the physician. The patient information includes links to definitions of medical jargon. The physician information cites medical journals and papers.

Oncology Channel gives detailed information about leukemia treatments for each of the subtypes of the disease, and may be useful for those who have already identified a specific type of leukemia.

Leukemia Hospitals
Although many hospitals treat leukemia, some are particularly renowned, or provide special services. Teaching hospitals, for example, often offer participation in clinical trials that are unavailable at other facilities. The sites below can acquaint you with some of the better known leukemia hospitals.
Insights for Leukemia Hospitals * Look for links to "Make an Appointment" or "Patient Referral" to find out how to become a patient at these hospitals. You'll either get a phone number or detailed information about the referral process. * In general, children's hospitals tend to have more non-medical programs for kids, such as day camps for kids with cancer or other entertainment-type events. If you're a parent with a child who has leukemia, look for links to other services offered by the hospital.

The Children's Hospital offers a full range of services, and their Center for Cancer and Blood Disorders treats more than 1,500 patients each year. The Web site offers a variety of links to resources, including cancer associations and a health library.
Lucile Packard Children's Hospital has experts on staff that specializes in bone marrow transplant and stem cell transplant. The Web site includes information about the physicians and services offered by the hospital. The site also offers a brief overview of the hospital's current research.

Children's Hospital Boston treats children and adolescents with leukemia. Their staff members are experts in the field of childhood leukemia, and the Web site includes detailed information about the physicians.
The list of hospitals above give a brief and general ideal about the services they offer.

Leukemia Organization

There are numerous nonprofit leukemia organizations that focus on raising funds for leukemia research, education, patient care and treatment. As part of their programs to increase awareness, organization Web sites provide a wealth of information for leukemia patients and families. Learn about their programs and research work, and access thorough, reputable information on leukemia at their sites.
Insights for Leukemia Organizations * If you're interested in contributing financially to any of these organizations, learn how your donations will be used by consulting that organization's "Mission Statement." This usually includes a brief overview of the association's focus and distribution of funds, such as the research they've supported. * If you're looking for financial assistance as a leukemia patient, contact these organizations directly through their "Contact" page. If the association is unable to help you, they may be able to guide you to the appropriate organization. * These organizations are also a good place to start if you want housing support or counseling during leukemia treatment. Again, contacting the association directly will usually get you a response.

The Leukemia & Lymphoma Society provides free information to the public. Also find information about financial support, treatment trials and advocacy. If you're looking to volunteer your time for leukemia, this organization has plenty of opportunities available.
The Children's Leukemia Research Association focuses on raising funds for leukemia research through donations. The association uses the money to fund medical research grants and to provide patient aid. Although the Web site lacks a professional look, the organization has a solid reputation.
Leukemia Research Foundation uses a variety of fundraising techniques that can be accessed online, including an eBay store and an Amazon "Wish List." Look for links under the "you can help" tab. The organization funds research aiming to discover causes and cures of leukemia.

REFERANCE PAGE
Broxmeyer H.E., Porcu P., Gaddy J., Kim C.H. 1998. Cord blood T-lymphocytes and natural killer cells and migration of cord blood cells immune reactivity. 11th Symposium on Molecular Biology of Hematopoietic. Bormio, Italy. (June 25) [Peer Reviewed] (Published)

Copelan E., Avalos B., Pohlman B., Penza S., Kalacyo M., Sobecks R., farag S., Andresen S., Molina A., Kuczkowski E., Lin T., Marcucci G., Elder P., O’Donnell L., Porcu P., Mrozek E., Bolwell B. 2001. Delay of transplantation beyond first relapse of low-grade NHL adversely influences outcome [Abstract]. ASH Annual Meeting 2001. Number. Abstr #2836 (Published)

Jordan M., Lairmore M., Thiel K., Porcu P., and Caligiuri MA. 2001. Clinical presentation of HTLV-1-associated leukemia. With both antiviral and antineoplastic therapy, the case report of successful treatment. ACP Meeting, Ohio Chapter 2001. Columbus, Ohio (Published)
Link B.K., Kahl B., Czuzman M., Powell B.L., Bartlett N., Leonard J.P., Ansell S., Porcu P., Byrd J.C., Lazarus H.M., Flinn I., Jones G.J., Levitt D., Hall W.C., Weiner G.J. 2001. A Phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma. ASH Annual Meeting 2001. No. Abstract #2540 [Peer Reviewed] (Published)
Magro C, Crowson N., Porcu P., and Nuovo J.G. 2001. Rapid diagnosis and molecular characterization of cutaneous B-cell infiltrates with in-situ RT-PCR analysis of paraffin-embedded, formalin-fixed tissue [Abstract]. ASH Annual Meeting 2001 (Published)
Porcu P., Farag S., Marcucci G., Avalos B., Rhoades C., Fisher B., Byrd J.C., Grever M.R. and Caligiuri M.A. 2001. Phase I trial of interleukin-2 (IL-2) and rituximab in patients with relapsed or refractory B-cell lymphomas (R/R-BCL). ASH Annual Meeting 2001. No. Abstr. #4710 [Peer Reviewed] (Published)
Porcu P., Pelletier R.P., Davis E.A., Baiocchi R.A., Eisenbeis C.F., Roychowdhury S., Nuovo G.J., Marsh W., Vanbuskirk A., Henry M.L., Ferguson R.M., Caligiuri M.A. 2001. Post-transplant lymph proliferative disorders following renal auto grafting: immunological and molecular monitoring identifies correlates of clinical response to reduction of immunosuppressant and antiviral therapy. AACR Annual Meeting 2001. New Orleans, LA.